| scholarly article | Q13442814 |
| P50 | author | Nic Gillings | Q26388661 |
| Søren Heissel | Q58930977 | ||
| Andreas Kjær | Q39183738 | ||
| Peter Højrup | Q40022709 | ||
| Paul R. Hansen | Q54936624 | ||
| P2093 | author name string | Christina Schjoeth-Eskesen | |
| Carsten Haagen Nielsen | |||
| P2860 | cites work | Optimized preparation and preliminary evaluation of [64Cu]–DOTA–trastuzumab for targeting ErbB2/Neu expression | Q57567743 |
| Biodistribution and dosimetry of pretargeted monoclonal antibody 2D12.5 and Y-Janus-DOTA in BALB/c mice with KHJJ mouse adenocarcinoma | Q73836705 | ||
| Monoclonal antibody pharmacokinetics and pharmacodynamics | Q81951721 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
| Monoclonal antibodies for copper-64 PET dosimetry and radioimmunotherapy | Q35124411 | ||
| A comparison of 111In- or 64Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT. | Q35650526 | ||
| Trastuzumab and breast cancer: developments and current status | Q36540576 | ||
| Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with (64)Cu-DOTA-trastuzumab | Q36680209 | ||
| 89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors | Q37148669 | ||
| A human, compact, fully functional anti-ErbB2 antibody as a novel antitumour agent. | Q37355464 | ||
| H6phospa-trastuzumab: bifunctional methylenephosphonate-based chelator with 89Zr, 111In and 177Lu. | Q37412579 | ||
| Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research | Q37478003 | ||
| Monoclonal antibodies in diagnosis and therapy | Q37755851 | ||
| Clinical pharmacokinetics of therapeutic monoclonal antibodies | Q37770555 | ||
| Matching chelators to radiometals for radiopharmaceuticals | Q38156660 | ||
| Comparison of DOTA and NODAGA as chelators for (64)Cu-labeled immunoconjugates | Q38933889 | ||
| Comparison of bifunctional chelates for (64)Cu antibody imaging | Q39692454 | ||
| Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with Cu-labeled trastuzumab PET. | Q39729571 | ||
| A simplified suite of methods to evaluate chelator conjugation of antibodies: effects on hydrodynamic radius and biodistribution | Q39855359 | ||
| Radiolabeling of trastuzumab with 177Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancer. | Q39855377 | ||
| Preclinical characterisation of 111In-DTPA-trastuzumab. | Q40491931 | ||
| Progression and treatment of HER2-positive breast cancer | Q43189081 | ||
| An improved method for conjugating monoclonal antibodies with N-hydroxysulfosuccinimidyl DOTA. | Q43582043 | ||
| 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer | Q44650607 | ||
| Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging | Q44944204 | ||
| Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer | Q48252174 | ||
| Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. | Q48532937 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | trastuzumab | Q412616 |
| P304 | page(s) | 227-233 | |
| P577 | publication date | 2015-04-24 | |
| P1433 | published in | Journal of Labelled Compounds and Radiopharmaceuticals | Q3186923 |
| P1476 | title | [(64) Cu]-labelled trastuzumab: optimisation of labelling by DOTA and NODAGA conjugation and initial evaluation in mice | |
| P478 | volume | 58 |
| Q90233040 | Comparison between Fractionated Dose and Single Dose of Cu-64 Trastuzumab Therapy in the NCI-N87 Gastric Cancer Mouse Model |
| Q38693617 | MANOTA: a promising bifunctional chelating agent for copper-64 immunoPET. |
| Q52990593 | New synthesis of phenyl-isothiocyanate C-functionalised cyclams. Bioconjugation and (64)Cu phenotypic PET imaging studies of multiple myeloma with the te2a derivative. |
| Q89529826 | Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology |
| Q91725280 | Site-specifically labeled 89Zr-DFO-trastuzumab improves immuno-reactivity and tumor uptake for immuno-PET in a subcutaneous HER2-positive xenograft mouse model |
| Q102388853 | Towards integration of 64Cu-DOTA-trastuzumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2 + breast cancer |
Search more.